[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 30 of about 30
1. Tanoue Y, Tanaka N, Suzuki Y, Hata S, Yokota A: A case report of endocrine cell carcinoma in the sigmoid colon with inferior mesenteric vein tumor embolism. World J Gastroenterol; 2009 Jan 14;15(2):248-51
Genetic Alliance. consumer health - Embolism.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case report of endocrine cell carcinoma in the sigmoid colon with inferior mesenteric vein tumor embolism.
  • We report a case of endocrine cell carcinoma in the sigmoid colon with inferior mesenteric vein (IMV) tumor embolism.
  • We performed colonoscopy, computed tomography and positron emission tomography, which disclosed sigmoid colon cancer with IMV tumor embolism.
  • The tumor was diagnosed as endocrine cell carcinoma (type 4, pSS, med, INFalpha, v3, n1, stage IIIb).
  • She was treated with chemotherapy of cisplatin (CDDP) + irinotecan (CPT11).
  • This case highlights the aggressiveness of endocrine cell carcinoma with tumor embolism, and it is essential to establish an accurate diagnosis and effective treatment.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Cancer. 1999 Dec;81(8):1351-5 [10604732.001]
  • [Cites] N Engl J Med. 2002 Jan 10;346(2):85-91 [11784874.001]
  • [Cites] Gastric Cancer. 2003;6(4):203-9 [14716513.001]
  • [Cites] Dis Colon Rectum. 2004 Feb;47(2):163-9 [15043285.001]
  • [Cites] Cancer Res. 1983 May;43(5):2088-93 [6187442.001]
  • [Cites] Surg Today. 2007;37(11):989-94 [17952533.001]
  • [Cites] Am J Clin Pathol. 1991 Mar;95(3):315-21 [1847579.001]
  • [Cites] Cancer. 1991 Jul 15;68(2):227-32 [1712661.001]
  • [Cites] Pathol Int. 1995 Aug;45(8):605-9 [7496507.001]
  • [Cites] South Med J. 1996 Sep;89(9):921-4 [8790320.001]
  • [Cites] Cancer. 1990 Jan 1;65(1):135-40 [2293859.001]
  • (PMID = 19132778.001).
  • [ISSN] 2219-2840
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC2653316
  •  go-up   go-down


2. Madanur MA, Battula N, Azam MO, Heaton N, Rela M: Chylous ascites after pancreatico-duodenectomy cholangiocarcinoma xenografts in nude mice. Hepatobiliary Pancreat Dis Int; 2007 Aug;6(4):416-9
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CA may be due to a consequence of occult obstruction of the proximal thoracic duct by malignant infiltration or tumor embolus.
  • Two patients developed loco-regional recurrences at a median follow up of 8 months (range 6-10 months).
  • CONCLUSIONS: CA as an uncommon postoperative complication requires frequent paracentesis, prolonged hospital stay, and delayed adjuvant chemotherapy.

  • Genetic Alliance. consumer health - Chylous Ascites.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17690041.001).
  • [ISSN] 1499-3872
  • [Journal-full-title] Hepatobiliary & pancreatic diseases international : HBPD INT
  • [ISO-abbreviation] HBPD INT
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  •  go-up   go-down


3. Shamberger RC, Ritchey ML, Haase GM, Bergemann TL, Loechelt-Yoshioka T, Breslow NE, Green DM: Intravascular extension of Wilms tumor. Ann Surg; 2001 Jul;234(1):116-21
MedlinePlus Health Information. consumer health - Wilms Tumor.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intravascular extension of Wilms tumor.
  • OBJECTIVE: To define the incidence and manifestations of and optimal therapy for children with intravascular extension of Wilms tumor.
  • METHODS: Children on a collaborative study of Wilms tumor who had intravascular extension into the inferior vena cava (IVC) or atrium were identified.
  • RESULTS: One hundred sixty-five of 2,731 patients had intravascular extension of Wilms tumor.
  • Sixty-nine had received preoperative therapy (55 with IVC extension and 14 with atrial extension) for a median of 8 weeks.
  • Complications during preoperative chemotherapy were seen in five patients (tumor embolism and tumor progression in one each, and three with adult respiratory distress syndrome, one of which was fatal).
  • The intravascular extension of the tumor regressed in 39 of 49 children with comparable pre- and posttherapy radiographic studies, including 7 of 12 in whom the tumor regressed from an atrial location, thus obviating the need for cardiopulmonary bypass.
  • The frequency of surgical complications was 26% in the primary resection group versus 13.2% in children with preoperative therapy.
  • When all the complications of therapy were considered, including those that occurred during the interval of preoperative chemotherapy (one of the five also had a surgical complication), the incidence of complications among those receiving preoperative therapy was not statistically different from the incidence among those who underwent primary resection.
  • CONCLUSIONS: Preoperative treatment of these children may facilitate resection by decreasing the extent of the tumor thrombus, but the overall frequency of complications is similar in both groups.

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1970 Aug;26(2):338-40 [4317965.001]
  • [Cites] J Urol. 1988 Nov;140(5 Pt 2):1113-8 [2846897.001]
  • [Cites] Am J Pediatr Hematol Oncol. 1986 Spring;8(1):75-8 [3013040.001]
  • [Cites] Med Pediatr Oncol. 1992;20(1):61-3 [1309207.001]
  • [Cites] J Pediatr Surg. 1992 Jul;27(7):912-5 [1322458.001]
  • [Cites] Surg Gynecol Obstet. 1992 Dec;175(6):507-14 [1333095.001]
  • [Cites] Cancer. 1993 Jun 15;71(12):4104-10 [8389661.001]
  • [Cites] J Urol. 1993 Sep;150(3):933-5 [8393945.001]
  • [Cites] J Pediatr Surg. 1994 Feb;29(2):229-31 [8176597.001]
  • [Cites] Pediatr Hematol Oncol. 1994 Sep-Oct;11(5):535-40 [7530031.001]
  • [Cites] Med Pediatr Oncol. 1996 Apr;26(4):268-71 [8600341.001]
  • [Cites] Br J Urol. 1996 Nov;78(5):772-6 [8976777.001]
  • [Cites] Postgrad Med J. 1996 Dec;72(854):749-50 [9015469.001]
  • [Cites] J Clin Oncol. 1998 Jan;16(1):237-45 [9440748.001]
  • [Cites] J Urol. 1986 Jul;136(1 Pt 2):312-7 [2425100.001]
  • [Cites] Ann Surg. 1986 Dec;204(6):693-7 [3024596.001]
  • [Cites] Urology. 1982 Jan;19(1):55-60 [6277066.001]
  • (PMID = 11420491.001).
  • [ISSN] 0003-4932
  • [Journal-full-title] Annals of surgery
  • [ISO-abbreviation] Ann. Surg.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA-42326
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC1421956
  •  go-up   go-down


Advertisement
4. Debourdeau P, Gligorov J, Teixeira L, Aletti M, Zammit C: [Malignant cardiac tumors]. Bull Cancer; 2004 Nov;91 Suppl 3:136-46

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The presence of metastatic tumor to the heart usually indicates widespread metastases.
  • Lung carcinomas are the most commonly encountered tumor followed by breast and pancreas cancer and melanoma.
  • The signs of cardiac neoplasms are divided into systemic symptoms (fever, arthralgias and myalgias), cardiac symptoms (congestive heart failure, arrhythmia, chest pain) and uncommon embolisms.
  • Due to its poor prognosis, treatment of cardiac metastases is restricted to best supportive care.
  • For primary cardiac neoplasms, surgery must be carefully discussed because operative intervention is often followed by rapid widespread metastases that adjuvant chemotherapy cannot avoid in most cases.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15899620.001).
  • [ISSN] 1769-6917
  • [Journal-full-title] Bulletin du cancer
  • [ISO-abbreviation] Bull Cancer
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 53
  •  go-up   go-down


5. Timovska YO, Pivnyuk VM, Oliynichenko GP, Anikushko MF, Zachartseva LM, Chekhun VF: Relation between pathomorphological response in tumors after neoadjuvant chemotherapy and clinico-morphological and molecular prognostic factors in patients with breast cancer. Exp Oncol; 2009 Dec;31(4):231-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Relation between pathomorphological response in tumors after neoadjuvant chemotherapy and clinico-morphological and molecular prognostic factors in patients with breast cancer.
  • AIM: To determine the correlation between tumor pathomorphological response (PMR) after neoadjuvant chemotherapy (NACT) and clinico-morphological and molecular prognostic factors in patients with breast cancer (BC), and to determine the possible impact of the PMR and estrogen receptors (ER), progesterone receptors (PR) and Her-2/neu BC status on the disease course.
  • METHODS: The data from the medical history of patients on IIB stage (T2N1M0, T3N0M0) (n = 247), who received treatment with NACT, were used.
  • RESULTS: PMR grade correlated with tumor differentiation grade (rho = 0.38; p 0.05) and BC subtypes (rho = 0.05; p > 0.05).
  • The patients with the same PMR grades didn't differ by the number of lymph node metastases (p > 0.05) and differed by the presence of embolus in tumor vessels (p 0.05).
  • CONCLUSION: The data of combined clinical, histological and immunohistochemical analysis have shown that PMR grades may serve as the criteria for individualization of adjuvant treatment of the patients with locally advanced BC.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Breast Neoplasms / drug therapy. Breast Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Cyclophosphamide / administration & dosage. Disease-Free Survival. Doxorubicin / administration & dosage. Female. Fluorouracil / administration & dosage. Humans. Immunohistochemistry. Kaplan-Meier Estimate. Lymphatic Metastasis / pathology. Middle Aged. Neoadjuvant Therapy. Prognosis. Receptor, ErbB-2 / genetics. Receptor, ErbB-2 / metabolism. Receptors, Estrogen / genetics. Receptors, Estrogen / metabolism. Receptors, Progesterone / genetics. Receptors, Progesterone / metabolism. Retrospective Studies

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20010529.001).
  • [ISSN] 1812-9269
  • [Journal-full-title] Experimental oncology
  • [ISO-abbreviation] Exp. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ukraine
  • [Chemical-registry-number] 0 / Receptors, Estrogen; 0 / Receptors, Progesterone; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; EC 2.7.10.1 / Receptor, ErbB-2; U3P01618RT / Fluorouracil
  •  go-up   go-down


6. Dzieciuchowicz ŁS, Słowinski M, Brzeziński JJ, Kycler W: Tumor embolus due to uterine cancer. Med Sci Monit; 2009 Oct;15(10):CS155-157
MedlinePlus Health Information. consumer health - Uterine Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor embolus due to uterine cancer.
  • The purpose of this paper is to report a case of tumor embolus of a brachial artery.
  • Because of an atypical appearance resembling fatty tissue, the embolic material was sent for microscopic examination that revealed carcinoma cells.
  • In spite of chemotherapy, the patient died one year later due to progression of the neoplastic disease.
  • The literature and common features of tumor embolus are reviewed.
  • This may be the first reported case of tumor peripheral arterial embolus caused by endometrial adenocarcinoma CONCLUSIONS: Although tumor emboli are a rarely described cause of acute limb ischemia, pathological examination of the embolic material seems to be indicated, especially in patients with an unknown source of emboli and in every case of an atypical appearance.
  • [MeSH-major] Embolism / complications. Embolism / pathology. Uterine Neoplasms / complications. Uterine Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19789516.001).
  • [ISSN] 1643-3750
  • [Journal-full-title] Medical science monitor : international medical journal of experimental and clinical research
  • [ISO-abbreviation] Med. Sci. Monit.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


7. Hoshimoto S, Hagiuda J, Igarashi N, Matsui H, Koyama Y, Miyakita M, Takanosu S: [A case of advanced gastric cancer with a tumor embolus in the portal vein successfully treated with TS-1 and CDDP]. Gan To Kagaku Ryoho; 2004 Jul;31(7):1079-81
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of advanced gastric cancer with a tumor embolus in the portal vein successfully treated with TS-1 and CDDP].
  • A 71-year-old man was admitted to our hospital in February 2002 with a diagnosis of advanced gastric cancer with a tumor embolus in the portal vein.
  • After 1 course of this regimen, medication was discontinued in accordance with the patient's request.
  • Despite no cancer treatment for almost 1.5 years, the primary lesion and the metastatic lymph nodes had decreased significantly in size and the tumor embolus in the portal vein had disappeared completely on the CT scan.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Neoplastic Cells, Circulating / pathology. Portal Vein / pathology. Stomach Neoplasms / drug therapy
  • [MeSH-minor] Aged. Cisplatin / administration & dosage. Drug Administration Schedule. Drug Combinations. Humans. Infusions, Intravenous. Lymph Nodes / pathology. Lymphatic Metastasis. Male. Oxonic Acid / administration & dosage. Pyridines / administration & dosage. Tegafur / administration & dosage

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15272589.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Drug Combinations; 0 / Pyridines; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


8. Kosugi M, Ono T, Yamaguchi H, Sato N, Dan K, Tanaka K, Takano T: Successful treatment of primary cardiac lymphoma and pulmonary tumor embolism with chemotherapy. Int J Cardiol; 2006 Jul 28;111(1):172-3
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful treatment of primary cardiac lymphoma and pulmonary tumor embolism with chemotherapy.
  • A 72-year-old man with a large mass in the right atrium and the pulmonary embolism by chest computed tomography was diagnosed as the primary cardiac B-cell lymphoma (PCL) with pulmonary tumor embolism and pericardial effusion.
  • Upon completion of initial chemotherapy, the mass was markedly reduced, and the pulmonary embolism disappeared on magnetic resonance imaging.
  • This rarely diagnosed entity is treatable with chemotherapy for both PCL and pulmonary embolism.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Heart Neoplasms / drug therapy. Lymphoma, B-Cell / drug therapy. Neoplastic Cells, Circulating. Pulmonary Embolism / drug therapy. Pulmonary Embolism / etiology
  • [MeSH-minor] Aged. Cyclophosphamide / therapeutic use. Doxorubicin / therapeutic use. Humans. Male. Prednisone / therapeutic use. Remission Induction. Vincristine / therapeutic use

  • Genetic Alliance. consumer health - Embolism.
  • MedlinePlus Health Information. consumer health - Pulmonary Embolism.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16129500.001).
  • [ISSN] 0167-5273
  • [Journal-full-title] International journal of cardiology
  • [ISO-abbreviation] Int. J. Cardiol.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] Ireland
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


9. Weijl NI, Rutten MF, Zwinderman AH, Keizer HJ, Nooy MA, Rosendaal FR, Cleton FJ, Osanto S: Thromboembolic events during chemotherapy for germ cell cancer: a cohort study and review of the literature. J Clin Oncol; 2000 May;18(10):2169-78
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Thromboembolic events during chemotherapy for germ cell cancer: a cohort study and review of the literature.
  • PURPOSE: To evaluate the risk of major thromboembolic complications in male germ cell cancer patients receiving cisplatin-based chemotherapy and to review the literature on this subject.
  • PATIENTS AND METHODS: One hundred seventy-nine germ cell cancer patients treated between January 1979 and May 1997 in our hospital were analyzed with respect to risk factors for developing thromboembolic events, such as baseline tumor characteristics, prior tumor therapy, administration of cytostatic agents, and the use of antiemetic drugs.
  • The patients were treated with a variety of combination chemotherapy regimens, primarily cisplatin-containing combination regimens.
  • RESULTS: Of the 179 patients, 15 patients (8.4%) were identified who developed a total of 18 major thromboembolic complications in the time period between the start of chemotherapy and 6 weeks after administration of the last cytostatic drug in first-line treatment.
  • 3%) were venous thromboembolic events, including 11 pulmonary embolisms.
  • 2 to 10.3) as antiemetic therapy were identified as risk factors for the development of major thromboembolic complications.
  • CONCLUSION: Germ cell cancer patients who receive chemotherapy, in particular those who have liver metastases or receive high doses of corticosteroids, are at considerable risk of developing thromboembolic complications.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Cisplatin / adverse effects. Germinoma / drug therapy. Testicular Neoplasms / drug therapy. Thromboembolism / chemically induced

  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10811682.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; Q20Q21Q62J / Cisplatin
  • [Number-of-references] 56
  •  go-up   go-down


10. Bernier J, Cooper JS, Pajak TF, van Glabbeke M, Bourhis J, Forastiere A, Ozsahin EM, Jacobs JR, Jassem J, Ang KK, Lefèbvre JL: Defining risk levels in locally advanced head and neck cancers: a comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (#22931) and RTOG (# 9501). Head Neck; 2005 Oct;27(10):843-50
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Defining risk levels in locally advanced head and neck cancers: a comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (#22931) and RTOG (# 9501).
  • BACKGROUND: In 2004, level I evidence was established for the postoperative adjuvant treatment of patients with selected high-risk locally advanced head and neck cancers, with the publication of the results of two trials conducted in Europe (European Organization Research and Treatment of Cancer; EORTC) and the United States (Radiation Therapy Oncology Group; RTOG).
  • Adjuvant chemotherapy-enhanced radiation therapy (CERT) was shown to be more efficacious than postoperative radiotherapy for these tumors in terms of locoregional control and disease-free survival.
  • However, additional studies were needed to identify precisely which patients were most suitable for such intense treatment.
  • A comparative analysis of the selection criteria, clinical and pathologic risk factors, and treatment outcomes was carried out using data pooled from these two trials.
  • There was also a trend in favor of CERT in the group of patients who had stage III-IV disease, perineural infiltration, vascular embolisms, and/or clinically enlarged level IV-V lymph nodes secondary to tumors arising in the oral cavity or oropharynx.
  • Patients who had two or more histopathologically involved lymph nodes without ECE as their only risk factor did not seem to benefit from the addition of chemotherapy in this analysis.
  • CONCLUSIONS: Subject to the usual caveats of retrospective subgroup analysis, our data suggest that in locally advanced head and neck cancer, microscopically involved resection margins and extracapsular spread of tumor from neck nodes are the most significant prognostic factors for poor outcome.
  • The addition of concomitant cisplatin to postoperative radiotherapy improves outcome in patients with one or both of these risk factors who are medically fit to receive chemotherapy.
  • [MeSH-major] Head and Neck Neoplasms / drug therapy. Head and Neck Neoplasms / radiotherapy. Randomized Controlled Trials as Topic
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Cisplatin / therapeutic use. Combined Modality Therapy. Humans. Neoplasm Recurrence, Local. Neoplasm Staging. Prognosis. Risk. Survival Analysis

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2005 Wiley Periodicals, Inc.
  • (PMID = 16161069.001).
  • [ISSN] 1043-3074
  • [Journal-full-title] Head & neck
  • [ISO-abbreviation] Head Neck
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 5U10 CA11488; United States / NCI NIH HHS / CA / 5U10 CA11488-33
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


11. Sekiyama T, Mizumura K, Kobayashi T, Hayashi S, Tsujino I, Hashimoto S: [A pulmonary tumor embolism which mimicked pulmonary tumor thrombotic microangiopathy caused by uterine cervical cancer]. Nihon Kokyuki Gakkai Zasshi; 2010 Aug;48(8):595-9
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A pulmonary tumor embolism which mimicked pulmonary tumor thrombotic microangiopathy caused by uterine cervical cancer].
  • Histological analysis of the transbronchial lung biopsy specimens obtained from the right lower lobe showed tumor cell embolism and fibrocellular intimal proliferation, but no thrombus formation or recanalization in the small arteries.
  • On the basis of these findings, we diagnosed pulmonary tumor embolism, not pulmonary tumor thrombotic microangiopathy (PTTM), because the pathological findings did not reveal either thrombus formation or recanalization, and the patient did not show hemodynamic effects such as hemolytic anemia, severe pulmonary hypertension, or disseminated intravascular coagulation.
  • Her symptoms improved after the administration of chemotherapy and radiation therapy.
  • Generally, a diagnosis of pulmonary tumor embolism and PTTM is difficult to establish in living patients.
  • It is important that therapy is started before the disease progresses to PTTM, if pulmonary tumor embolism is diagnosed.


12. Ishiko T, Doi K, Beppu T, Hirota M, Ogawa M: [A case report of advanced huge hepatocellular carcinoma (H.C.C.) accompanied by tumor embolism to the inferior caval vein (Vv3) that was treated with surgical extended right lobectomy after multimodal therapy]. Gan To Kagaku Ryoho; 2002 Nov;29(12):2416-20
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case report of advanced huge hepatocellular carcinoma (H.C.C.) accompanied by tumor embolism to the inferior caval vein (Vv3) that was treated with surgical extended right lobectomy after multimodal therapy].
  • We performed multimodal therapy for a huge hepatocellular carcinoma with tumor embolism (Vv3), for which excision was judged impossible.
  • After treatment, a hepatectomy to the primary lesion was finally carried out and long-term survival was achieved.
  • A tumor embolism, which invaded the inferior vena cava, was also seen.
  • A percutaneous transhepatic portal embolism (PTPE) was carried out against the right portal vein to increase in the left lobe capacity.
  • The chemo-radiotherapy (36 Gy to the right hepatic vein and systemic administration of CDDP) and transcatheter arterial chemoembolization were added to the feeding arteries of the hepatic tumor.
  • When a decrease in the postcaval vein tumor embolism was observed, the extended right hepatic lobectomy was performed.
  • Though lung metastasis and new lesions in left lobe were seen in a recurrence, two years and ten months since the start of the systemic chemotherapy.
  • This case suggested that even if a huge liver cancer with vascular invasion is judged impossible to excise, multimodal therapy with the aim of surgical treatment helps retain the possibility to later chose hepatectomy for the primary lesion and improve prognosis.
  • [MeSH-major] Carcinoma, Hepatocellular / therapy. Hepatectomy. Liver Neoplasms / therapy. Neoplastic Cells, Circulating / pathology
  • [MeSH-minor] Cisplatin / administration & dosage. Combined Modality Therapy. Embolization, Therapeutic. Humans. Male. Middle Aged. Vena Cava, Inferior / pathology

  • Genetic Alliance. consumer health - Embolism.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12484089.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin
  •  go-up   go-down


13. Yu L, Tan GS, Xiang XH, Guo WB, Li HP, Huang YH, Yang JY: [Comparison of uterine artery chemoembolization and internal iliac arterial infusion chemotherapy for the combining treatment for women with locally advanced cervical cancer]. Ai Zheng; 2009 Apr;28(4):402-7
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Comparison of uterine artery chemoembolization and internal iliac arterial infusion chemotherapy for the combining treatment for women with locally advanced cervical cancer].
  • BACKGROUND AND OBJECTIVE: Uterine artery chemoembolization (UACE) and internal iliac arterial infusion chemotherapy (IAIC) are important methods to treat cervical cancer.
  • This study was to evaluate the curative effects of UACE and IAIC on the combining treatment for women with locally advanced cervical cancer.
  • The IAIC group was treated by bilateral internal iliac arterial infusion chemotherapy.
  • All patients were treated by carboplatin-based combining chemotherapy.
  • RESULTS: The tumor regression rate of the UACE group was 64.1%, which was significantly higher than 47.0% in the IAIC group (P=0.023).
  • The negative percentage of tumor embolus within lymphovascular space was lower in the UACE group than in the IAIC group (87.3% vs. 97.1%, P=0.072).
  • CONCLUSIONS: UACE followed by preoperative radiotherapy can more effectively reduce the tumor volume of locally advanced cervical cancer compared with IAIC.
  • But UACE does not increase the pathological complete response rate and not decrease the pelvic lymph node metastasis rate, the postoperative recurrence rate, and tumor embolus within lymphovascular space.The effect of UACE on the long-term survival of locally advanced cervical cancer needs to be further evaluated.
  • [MeSH-major] Carcinoma, Squamous Cell / therapy. Chemoembolization, Therapeutic. Infusions, Intra-Arterial. Uterine Cervical Neoplasms / therapy
  • [MeSH-minor] Adenocarcinoma / pathology. Adenocarcinoma / therapy. Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brachytherapy. Carboplatin / administration & dosage. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Hysterectomy / methods. Iliac Artery. Iridium Radioisotopes / therapeutic use. Lymphatic Metastasis. Middle Aged. Neoplasm Recurrence, Local. Neoplasm Staging. Neoplasm, Residual. Remission Induction. Retrospective Studies. Tumor Burden. Uterine Artery. Young Adult


14. Grass H, Schuff A, Staak M, Dienes HR, von Both I: Tumor embolism as a cause of an unexpected death: a case report. Pathol Res Pract; 2003;199(5):349-52
MedlinePlus Health Information. consumer health - Thyroid Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor embolism as a cause of an unexpected death: a case report.
  • The autopsy revealed a bulky thyroid tumor with venous invasion, leading to a massive pulmonary tumor embolism.
  • Furthermore, microscopy identified the tumor as a rare pleomorphic myxoid sarcoma.
  • Thus, the patient died of a large pulmonary tumor embolism originating from this rare sarcoma, and not of acute pulmonary dysfunction of any other means.
  • [MeSH-major] Cause of Death. Neoplastic Cells, Circulating / pathology. Pulmonary Embolism / etiology. Sarcoma / pathology. Thyroid Neoplasms / pathology
  • [MeSH-minor] Anti-Bacterial Agents / therapeutic use. Female. Humans. Middle Aged. Pneumonia / complications. Pneumonia / drug therapy

  • Genetic Alliance. consumer health - Embolism.
  • MedlinePlus Health Information. consumer health - Pulmonary Embolism.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12908527.001).
  • [ISSN] 0344-0338
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents
  •  go-up   go-down


15. Hiraki M, Sato S, Kai K, Ohtsuka T, Kohya N, Kitajima Y, Nakafusa Y, Tokunaga O, Miyazaki K: A long-time survivor of alpha-fetoprotein-producing gastric cancer successfully treated by fluoropyrimidine-based chemotherapy: a case study. Clin J Gastroenterol; 2009 Oct;2(5):331-337

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A long-time survivor of alpha-fetoprotein-producing gastric cancer successfully treated by fluoropyrimidine-based chemotherapy: a case study.
  • A 67-year-old male with advanced gastric cancer and lymph node metastasis as well as a tumor embolus in the portal vein was treated by S-1/cisplatin therapy.
  • After one course of chemotherapy, the patient showed stable disease; the serum level of alpha-fetoprotein also decreased to 626 ng/ml after a transient increase, and therefore reduction surgery was performed.
  • A total gastrectomy with a distal pancreatectomy, splenectomy, and regional lymph node dissection was performed.
  • There were no metastatic foci in the resected lymph nodes, presumably due to the preoperative chemotherapy.
  • S-1/cisplatin therapy was continued after the operation to treat the remaining tumor embolus in the portal vein.
  • After one course of this therapy, the tumor embolus disappeared.
  • Therefore, the chemotherapy was changed to paclitaxel monotherapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gastric Cancer. 2003;6 Suppl 1:71-81 [12775024.001]
  • [Cites] World J Surg Oncol. 2007 Jul 16;5:79 [17634124.001]
  • [Cites] Hepatogastroenterology. 2006 May-Jun;53(69):338-41 [16795967.001]
  • [Cites] Hepatogastroenterology. 2005 Jan-Feb;52(61):326-8 [15783061.001]
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92 (3):205-16 [10655437.001]
  • [Cites] Nihon Shokakibyo Gakkai Zasshi. 2008 Oct;105(10):1489-95 [18840987.001]
  • [Cites] Acta Gastroenterol Belg. 2006 Jul-Sep;69(3):330-7 [17168134.001]
  • [Cites] J Clin Oncol. 1996 Jan;14(1):176-82 [8558194.001]
  • [Cites] Surg Today. 2002;32(5):429-33 [12061695.001]
  • [Cites] Cancer Chemother Pharmacol. 2005 Aug;56(2):138-44 [15827767.001]
  • [Cites] Lancet Oncol. 2008 Mar;9(3):215-21 [18282805.001]
  • [Cites] Anticancer Res. 2004 Jul-Aug;24(4):2495-501 [15330204.001]
  • [Cites] Am J Clin Oncol. 1998 Aug;21(4):416-9 [9708646.001]
  • [Cites] Intern Med. 2000 Mar;39(3):223-7 [10772124.001]
  • [Cites] Cancer. 1998 Oct 1;83(7):1300-6 [9762929.001]
  • [Cites] Radiology. 1990 Mar;174(3 Pt 1):811-4 [1689502.001]
  • [Cites] Kurume Med J. 2002;49(3):157-60 [12471731.001]
  • [Cites] Dig Surg. 2002;19(5):359-65; discussion 365 [12435906.001]
  • [Cites] Gastric Cancer. 2003;6 Suppl 1:66-70 [12775023.001]
  • [Cites] Am J Gastroenterol. 1992 Mar;87(3):321-5 [1371637.001]
  • [Cites] Gastric Cancer. 1998 Dec;1(1):10-24 [11957040.001]
  • [Cites] Surg Today. 2004;34(9):784-7 [15338356.001]
  • [Cites] Cancer Lett. 2007 Dec 8;258(1):45-54 [17892912.001]
  • [Cites] Gan To Kagaku Ryoho. 2001 Dec;28(13):2079-82 [11791389.001]
  • [Cites] Oncology. 2004;66(6):445-9 [15452373.001]
  • [Cites] Oncol Rep. 2006 Oct;16(4):721-7 [16969485.001]
  • [Cites] Hepatogastroenterology. 2007 Jun;54(76):1302-4 [17629094.001]
  • [Cites] J Gastroenterol. 2003;38(6):540-7 [12825129.001]
  • [Cites] Nihon Shokakibyo Gakkai Zasshi. 2005 Dec;102(12):1523-8 [16372769.001]
  • [Cites] Oncology. 2004;66(3):226-33 [15218314.001]
  • [Cites] Intern Med. 2004 Feb;43(2):106-10 [15005251.001]
  • [Cites] Clin Cancer Res. 1998 Apr;4(4):1013-9 [9563897.001]
  • [Cites] Int J Cancer. 2006 Oct 15;119(8):1927-33 [16736497.001]
  • [Cites] Gan To Kagaku Ryoho. 2008 Feb;35(2):299-301 [18281769.001]
  • [Cites] Gastric Cancer. 2001;4(1):43-52 [11706627.001]
  • [Cites] Gan To Kagaku Ryoho. 2005 Jun;32(6):855-8 [15984531.001]
  • [Cites] Surg Today. 2002;32(12 ):1075-80 [12541026.001]
  • (PMID = 26192608.001).
  • [ISSN] 1865-7257
  • [Journal-full-title] Clinical journal of gastroenterology
  • [ISO-abbreviation] Clin J Gastroenterol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Keywords] NOTNLM ; Chemoresistance / Dihydropyrimidine dehydrogenase / Ortate phosphoribosyltransferase / Thymidylate synthase
  •  go-up   go-down


16. Bozaci EA, Taşkin S, Gürkan O, Atasoy C, Ersoy ZG, Erekul S, Numanoğlu N, Ortaç F: Intracavitary cardiac metastasis and pulmonary tumor emboli of choriocarcinoma: the first case diagnosed and treated without surgical intervention. Gynecol Oncol; 2005 Dec;99(3):753-6
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intracavitary cardiac metastasis and pulmonary tumor emboli of choriocarcinoma: the first case diagnosed and treated without surgical intervention.
  • Its pulmonary tumor embolism and cardiac metastasis are very rarely encountered, of which antemortem diagnosis is even more rare.
  • CASE: To our knowledge, we present the first case of intracavitary cardiac metastasis and pulmonary tumor emboli of choriocarcinoma diagnosed and treated without any surgical intervention.
  • Multi-agent chemotherapy led to almost complete regression of cardiac and pulmonary lesions and normalization of beta-hCG levels.
  • As the tumor is highly sensitive, chemotherapy together with biochemical and radiological monitoring constitutes an effective treatment modality if cardiopulmonary functions are not deteriorating.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Choriocarcinoma / drug therapy. Choriocarcinoma / secondary. Heart Neoplasms / drug therapy. Heart Neoplasms / secondary. Lung Neoplasms / drug therapy. Lung Neoplasms / secondary

  • Genetic Alliance. consumer health - Choriocarcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16115666.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Geschwind JF, Dagli MS, Vogel-Claussen J, Seifter E, Huncharek MS: Metastatic breast carcinoma presenting as a large pulmonary embolus: case report and review of the literature. Am J Clin Oncol; 2003 Feb;26(1):89-91
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic breast carcinoma presenting as a large pulmonary embolus: case report and review of the literature.
  • Involvement of the pulmonary vasculature by carcinoma of the breast typically occurs in the form of microscopic tumor emboli involving the small arteries, arterioles, or capillaries.
  • Obstruction of a large pulmonary artery by a tumor embolus has not been reported.
  • We describe a patient with a history of breast carcinoma diagnosed 5 years previously who sought treatment for dyspnea and a large mass in the right pulmonary artery suggestive of a pulmonary embolus.
  • After failure of both systemic and intraarterial thrombolytic therapy, a biopsy of the mass was obtained, which revealed adenocarcinoma of the breast.
  • Systemic chemotherapy with doxorubicin and cyclophosphamide was initiated and resulted in the complete resolution of her symptoms.
  • [MeSH-major] Adenocarcinoma / complications. Adenocarcinoma / secondary. Breast Neoplasms / complications. Breast Neoplasms / pathology. Neoplastic Cells, Circulating. Pulmonary Embolism / diagnosis. Pulmonary Embolism / etiology
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biopsy. Bone Neoplasms / secondary. Diagnosis, Differential. Female. Humans. Middle Aged

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Pulmonary Embolism.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12576931.001).
  • [ISSN] 0277-3732
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 7
  •  go-up   go-down


18. Lee HH, Joh JW, Park JH, Lee KW, Heo JS, Choi SH, Kim SJ, Lee SK: Microvascular tumor embolism: independent prognostic factor after liver transplantation in hepatocellular carcinoma. Transplant Proc; 2005 Mar;37(2):1251-3
MedlinePlus Health Information. consumer health - Liver Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Microvascular tumor embolism: independent prognostic factor after liver transplantation in hepatocellular carcinoma.
  • Microscopic tumor cell dissemination may be a more important factor in the recurrence of hepatocellular carcinoma (HCC) after liver transplantation, probably because of posttransplant immunosuppression.
  • The presence of microvascular tumor embolism was undetermined as a factor for HCC recurrence after orthotopic liver transplantation (OLT).
  • This study evaluated whether microvascular tumor embolism affects recurrence-free survival and correlates with other clinicopathologic factors after OLT among patients with HCC.
  • Among 41 patients without microvascular tumor embolism, 1-year, 2-year, and 5-year recurrence-free survival rates were all 97.6%, while these rates were 77.3%, 68.2%, and 59.7%, respectively, for 31 patients (43.1%) with microvascular tumor embolism (P = .0006).
  • The 5-year recurrence-free survival rate showed significant differences for a pT2 tumor (P = .0073), for maximal tumor size <3 cm (P = .0328), for > or =5 cm solitary tumor (P = .0095), and for the presence of a tumor capsule (P = .0012), within the Milan criteria (P = .0376).
  • At multivariate analysis, significant independent predictors for HCC recurrence were microvascular tumor embolism and histopathologic grade.
  • In conclusion, microvascular tumor embolism is an independent predictor of HCC recurrence after liver transplantation.
  • Although OLT is a safe and effective treatment for HCC within the Milan criteria, the presence of microvascular tumor embolism at pathologic examination can predict its recurrence.
  • In these cases, the feasibility of immunosuppressive therapy or adjuvant chemotherapy must be considered to prevent tumor recurrence.
  • [MeSH-major] Carcinoma, Hepatocellular / blood supply. Carcinoma, Hepatocellular / surgery. Embolism / epidemiology. Liver Neoplasms / blood supply. Liver Neoplasms / surgery. Liver Transplantation. Microcirculation / pathology
  • [MeSH-minor] Adult. Analysis of Variance. Disease-Free Survival. Humans. Prognosis. Recurrence. Retrospective Studies. Survival Analysis. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Embolism.
  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15848686.001).
  • [ISSN] 0041-1345
  • [Journal-full-title] Transplantation proceedings
  • [ISO-abbreviation] Transplant. Proc.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Tsuchiya T, Hiramatsu K, Tanaka H, Machiki Y, Sakuragawa T, Otsuji H, Hara T, Kimura A, Yoshida K, Hosoya J, Kojima T, Kato K: [A Case of gastric endocrine cell carcinoma successfully treated by FU plus irinotecan(CPT-11)adjuvant therapy against recurrent metastases]. Gan To Kagaku Ryoho; 2009 Dec;36(13):2641-4
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A Case of gastric endocrine cell carcinoma successfully treated by FU plus irinotecan(CPT-11)adjuvant therapy against recurrent metastases].
  • A case of gastric endocrine cell carcinoma successfully treated by FU (5-FU/UFT) +irinotecan (CPT-11) adjuvant therapy against recurrent metastases is reported with some discussion.
  • Seven months after operation, recurrent liver metastases with tumor embolism of the portal vein were revealed by enhanced CT examination.
  • FU (5-FU/UFT) +CPT-11 was done as the first-line adjuvant chemotherapy.
  • Metastatic lesion of the liver and portal vein tumor embolism was decreased.
  • Tumor marker CA19-9 level was also decreased and within normal limits.
  • This therapy was evaluated as a partial response (PR) in twelve months and the patient died three years and eight months after operation.
  • Gastric endocrine cell carcinoma is known as a potentially highly malignant tumor.
  • But in our case FU+CPT-11 controlled growth of the recurrent tumor.
  • Based on this finding, we recommend adjuvant chemotherapy by FU+CPT-11 for gastric endocrine cell carcinoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Stomach Neoplasms / therapy
  • [MeSH-minor] Aged. Antimetabolites, Antineoplastic / administration & dosage. Antineoplastic Agents, Phytogenic / administration & dosage. Camptothecin / administration & dosage. Camptothecin / analogs & derivatives. Chemotherapy, Adjuvant. Fluorouracil / administration & dosage. Gastrectomy. Humans. Lymph Node Excision. Male. Neoplasm Metastasis. Tegafur / administration & dosage. Uracil / administration & dosage

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20009471.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents, Phytogenic; 1548R74NSZ / Tegafur; 56HH86ZVCT / Uracil; 7673326042 / irinotecan; U3P01618RT / Fluorouracil; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


20. Tucakovic M, Bascom R, Bascom PB: Pulmonary medicine and palliative care. Best Pract Res Clin Obstet Gynaecol; 2001 Apr;15(2):291-304
MedlinePlus Health Information. consumer health - Palliative Care.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Parenchymal metastases are typically multifocal and respond to chemotherapy, with a limited role for pulmonary metastatectomy.
  • Pulmonary tumour embolism is frequently associated with lymphangitic carcinomatosis, and is most common in choriocarcinoma.
  • Opiates are effective at relieving dyspnoea associated with effusions, metatases, and lymphangitic tumour spread.
  • Non-pharmacological therapies include energy conservation, home redesign, and dyspnoea relief strategies, including pursed lip breathing, relaxation, oxygen, circulation of air with a fan, and attention to spiritual suffering.
  • Identification and treatment of gastroesophageal reflux, sinusitis, and asthma can improve many patients' coughs.
  • [MeSH-major] Genital Neoplasms, Female / complications. Genital Neoplasms, Female / therapy. Lung Diseases / etiology. Palliative Care / methods
  • [MeSH-minor] Aged. Aged, 80 and over. Airway Obstruction / therapy. Cough / therapy. Dyspnea / therapy. Female. Humans. Lung Neoplasms / diagnosis. Lung Neoplasms / secondary. Lung Neoplasms / therapy. Meige Syndrome / surgery. Pleural Effusion, Malignant / therapy. Pulmonary Embolism / diagnosis. Pulmonary Embolism / drug therapy. Quality of Life. Vena Cava Filters

  • MedlinePlus Health Information. consumer health - Lung Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2001 Harcourt Publishers Ltd.
  • (PMID = 11358403.001).
  • [ISSN] 1521-6934
  • [Journal-full-title] Best practice & research. Clinical obstetrics & gynaecology
  • [ISO-abbreviation] Best Pract Res Clin Obstet Gynaecol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 65
  •  go-up   go-down


21. Matsumoto S, Ahmed AR, Kawaguchi N, Manabe J, Matsushita Y: Results of surgery for malignant fibrous histiocytomas of soft tissue. Int J Clin Oncol; 2003 Apr;8(2):104-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Results of surgery for malignant fibrous histiocytomas of soft tissue.
  • adjuvant chemotherapy, (4). size, (5).
  • RESULTS: Local recurrence after primary surgery done at the authors' institute was the most significant prognostic factor, where 20 of 123 patients developed local recurrence ( P < 0.0001).
  • The cause of local recurrence were insufficient surgical margin in 16 patients, while in 4, local recurrences were related to lymph node metastasis, skip metastasis, and tumor embolism.
  • The local recurrence rate for each surgical procedure was 75% for intralesional, 44.4% for marginal, 30.8% for inadequate wide, 12.3% for adequate wide, and 5% for curative procedures.
  • In patients with a history of recurrent tumor or infiltrative pattern, local recurrence was not observed after a curative procedure, but occurred even after an adequate wide procedure.
  • An adequate wide procedure for primary tumors and a curative procedure for recurrent tumors and tumors with an infiltrative pattern provide safe surgical margins.
  • [MeSH-major] Histiocytoma, Benign Fibrous / pathology. Histiocytoma, Benign Fibrous / surgery. Neoplasm Recurrence, Local / pathology. Soft Tissue Neoplasms / pathology. Soft Tissue Neoplasms / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Biopsy, Needle. Cohort Studies. Humans. Immunohistochemistry. Middle Aged. Multivariate Analysis. Neoplasm Staging. Probability. Prognosis. Proportional Hazards Models. Reoperation. Retrospective Studies. Risk Assessment. Survival Rate. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12720103.001).
  • [ISSN] 1341-9625
  • [Journal-full-title] International journal of clinical oncology
  • [ISO-abbreviation] Int. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


22. Kröger K, Weiland D, Ose C, Neumann N, Weiss S, Hirsch C, Urbanski K, Seeber S, Scheulen ME: Risk factors for venous thromboembolic events in cancer patients. Ann Oncol; 2006 Feb;17(2):297-303
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Cancer patients of the Department of Internal Medicine (Cancer Research) of the Essen University Medical School (Tumor Clinics), Germany, were examined and questioned with the aim of identifying those who run a high risk of deep vein thrombosis (DVT).
  • PATIENTS AND METHODS: Between September 2002 and April 2003, cancer therapy and DVT risk factors of 507 cancer patients (53% males, 47% females, mean age 56+/-12 years) were documented.
  • During a mean follow-up of 8+/-5 months, 60 patients (12%) suffered from new venous thromboembolic events (VTE): 28 at the lower limb, 25 at the upper limb and 13 pulmonary embolisms.
  • RESULTS: The following factors were considered as predictive for an increased VTE risk: inpatient treatment (P<0.0001), prior DVT in medical history (P=0.0275), DVT in family (P=0.0598), chemotherapy (P=0.0080), fever (P=0.0093) and CRP (P<0.001).

  • MedlinePlus Health Information. consumer health - Deep Vein Thrombosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16282243.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anticoagulants; 0 / Antineoplastic Agents; 9007-41-4 / C-Reactive Protein
  •  go-up   go-down


23. Ramos M, Benavente S, Giralt J: Management of squamous cell carcinoma of the head and neck: updated European treatment recommendations. Expert Rev Anticancer Ther; 2010 Mar;10(3):339-44
MedlinePlus Health Information. consumer health - Head and Neck Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of squamous cell carcinoma of the head and neck: updated European treatment recommendations.
  • Risk factors for adjuvant radiotherapy are stage III-IV, perineural involvement or vascular tumor embolism.
  • For patients with nonresectable disease we recommend treatment with concomitant chemoradiation, although this has important acute and late toxicity.
  • Concomitant EGF receptor inhibitors and taxane-based induction chemotherapy are new strategies under study that have demonstrated some benefits but are not yet the standard treatment.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Carcinoma, Squamous Cell / therapy. Head and Neck Neoplasms / therapy
  • [MeSH-minor] Combined Modality Therapy. Europe / epidemiology. Humans. Neoplasm Staging. Practice Guidelines as Topic. Radiotherapy, Adjuvant / adverse effects. Radiotherapy, Adjuvant / methods. Radiotherapy, Intensity-Modulated / methods. Risk Factors

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20214515.001).
  • [ISSN] 1744-8328
  • [Journal-full-title] Expert review of anticancer therapy
  • [ISO-abbreviation] Expert Rev Anticancer Ther
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 35
  •  go-up   go-down


24. Nohgawa M, Moriguchi T, Tsudo M: [Intravascular lymphomatosis diagnosed by bone marrow biopsy]. Rinsho Ketsueki; 2000 Jul;41(7):607-11
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Bone marrow aspiration revealed a normal cellular marrow with mild hemophagocytosis, but no tumor cells were detected.
  • After admission, respiratory failure due to multiple pulmonary embolisms progressed, and continuous infusion of heparin had no apparent effect.
  • Chemotherapy with the CHOP regimen was immediately instituted.
  • After eight courses of CHOP, low-dose etoposide therapy was administered, and no symptoms of relapse were noticed.
  • The diagnosis of IVL is difficult because it does not form masses of tumor cells.

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11020986.001).
  • [ISSN] 0485-1439
  • [Journal-full-title] [Rinshō ketsueki] The Japanese journal of clinical hematology
  • [ISO-abbreviation] Rinsho Ketsueki
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] JAPAN
  •  go-up   go-down


25. Mehta RS, Schubbert T, Marshall J, Carpenter PM: Rational and successful use of carboplatin and albumin-bound paclitaxel in a patient with recurrent metaplastic carcinoma who presented with multi-organ tumor emboli. Clin Breast Cancer; 2009 Feb;9(1):56-9
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rational and successful use of carboplatin and albumin-bound paclitaxel in a patient with recurrent metaplastic carcinoma who presented with multi-organ tumor emboli.
  • We demonstrate successful treatment of recurrent chondroid-metaplastic breast cancer.
  • A diagnosis of tumor embolism was suspected when a chest radiograph performed as part of a work-up for stroke demonstrated several lung nodules, with 1 lung nodule invading the pulmonary vein and extending into the left atrium-the source of tumor emboli.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Breast Neoplasms / drug therapy. Metaplasia / drug therapy. Neoplasm Recurrence, Local / drug therapy
  • [MeSH-minor] Albumin-Bound Paclitaxel. Albumins / administration & dosage. Carboplatin / administration & dosage. Female. Humans. Middle Aged. Paclitaxel / administration & dosage. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19299243.001).
  • [ISSN] 1526-8209
  • [Journal-full-title] Clinical breast cancer
  • [ISO-abbreviation] Clin. Breast Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA062203
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Albumin-Bound Paclitaxel; 0 / Albumins; BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


26. Zeni PT Jr, Blank BG, Peeler DW: Use of rheolytic thrombectomy in treatment of acute massive pulmonary embolism. J Vasc Interv Radiol; 2003 Dec;14(12):1511-5
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Use of rheolytic thrombectomy in treatment of acute massive pulmonary embolism.
  • The purpose of this study was to evaluate the efficacy of thrombus removal using the RTC in patients with acute massive pulmonary embolism (PE).
  • MATERIALS AND METHODS: Seventeen patients (mean age, 51.7 + 16.6 years; range, 30-86 years; 9 men, 8 women) with massive PE initially diagnosed by computed tomography (CT) or VQ scan and confirmed by pulmonary angiography were treated with the RTC.
  • Six patients had contraindications to thrombolytic therapy.
  • One patient presented with renal cell carcinoma and tumor embolus as suspected cause of PE.
  • Treatment resulted in immediate angiographic improvement and initial relief of PE symptoms (improvement in dyspnea and oxygen saturation) in 16 of 17 patients.
  • One patient developed heart block during the procedure, and further treatment with the RTC was discontinued.
  • After thrombectomy, 10 patients received adjunctive reteplase thrombolysis for treatment of residual thrombus, and 12 received inferior vena cava (IVC) filters.
  • In the patient with renal cell carcinoma, histopathologic analysis of the evacuated material confirmed tumor origin of the embolism.
  • There were two deaths, both within 24 hours of treatment and secondary to PE.
  • One death occurred in a patient who had only minimal thrombus removal after treatment with the RTC and no thrombolysis.
  • Further evaluation in a larger cohort of patients is warranted to assess whether this treatment may offer an alternative or complement to thrombolysis or surgical thrombectomy.
  • [MeSH-major] Fibrinolytic Agents / therapeutic use. Pulmonary Embolism / drug therapy. Pulmonary Embolism / surgery. Thrombectomy
  • [MeSH-minor] Acute Disease. Adult. Aged. Aged, 80 and over. Catheterization / adverse effects. Catheterization / instrumentation. Catheterization / methods. Female. Humans. Male. Middle Aged. Retrospective Studies. Treatment Outcome

  • Genetic Alliance. consumer health - Embolism.
  • MedlinePlus Health Information. consumer health - Pulmonary Embolism.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Vasc Interv Radiol. 2004 Sep;15(9):1024; author reply 1024 [15470786.001]
  • (PMID = 14654484.001).
  • [ISSN] 1051-0443
  • [Journal-full-title] Journal of vascular and interventional radiology : JVIR
  • [ISO-abbreviation] J Vasc Interv Radiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Fibrinolytic Agents
  •  go-up   go-down


27. Klepacka T, Woźniak W, Liebhart M, Michalak E, Kuczabski M, Rychłowska M: [Local recurrences after salvage operations in the therapy of osteogenic sarcoma cases - an analysis of adverse effects based on studied cases]. Med Wieku Rozwoj; 2000 Apr-Jun;4(2 Suppl 2):67-76
MedlinePlus Health Information. consumer health - Bone Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Local recurrences after salvage operations in the therapy of osteogenic sarcoma cases - an analysis of adverse effects based on studied cases].
  • Therapeutic approach in osteogenic sarcoma until 1982 was connected mainly with surgery.
  • Introduction of chemotherapy to the therapeutic protocols of osteogenic sarcoma improved the 5 years survival of patients with osteogenic sarcoma from 20% to 60-70%.
  • The approach to surgical treatment was also changed.
  • The principle of this treatment is usually to perform an operation to spare the limb with an intraoperative frozen section examination of bone marrow.
  • In our Institute during the last 14 years about 300 cases were diagnosed, out of which about 200 were treated surgically, among these about 50% underwent treatment by salvage operations.
  • Five of these cases were tumours of distal metaphysis of the femur, one case of proximal metaphysis of the tibia and one case of proximal metaphysis of the humeral bone.
  • Various factors playing a role in therapeutic adversities were analysed.
  • Among these were: radical surgery, grade of differentiation of the tumour, histological subtype, soft tissue infiltration, reaction to preoperative therapy and the type of chemotherapy.
  • The conducted analysis indicates the role played by sparing surgery in adversities in therapy (3 cases).
  • Attention was also given to the distinct tendency of osteogenic sarcoma to produce vascular embolism which is a source of haematogenously spreading metastases.
  • In 7 cases vascular tumour embolism caused the appaerance of metastatic focuses adjacent to the primary tumour.
  • A certain role in therapeutic adverities is played by the lack of response to preoperative chemotherapy (4/7 cases).
  • [MeSH-major] Bone Neoplasms / surgery. Neoplasm Recurrence, Local. Osteosarcoma / surgery. Salvage Therapy / adverse effects
  • [MeSH-minor] Adolescent. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Child. Female. Humans. Male. Risk Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11178330.001).
  • [Journal-full-title] Medycyna wieku rozwojowego
  • [ISO-abbreviation] Med Wieku Rozwoj
  • [Language] pol
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


28. Tajiri S, Ozawa H, Komatsu M, Hayama N, Kondo Y, Ito M, Oka A, Urano T, Kondo T: [A case of choriocarcinoma of suspected lung origin manifesting pulmonary embolism]. Nihon Kokyuki Gakkai Zasshi; 2008 Dec;46(12):1029-33
MedlinePlus Health Information. consumer health - Pulmonary Embolism.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of choriocarcinoma of suspected lung origin manifesting pulmonary embolism].
  • She was given a diagnosis of COP based on TBLB specimen and CT findings and received steroid pulse therapy at the hospital.
  • Three months after her first visit she was referred to our hospital because her symptoms had not resolved despite receiving steroid therapy.
  • Although anticoagulation therapy was initiated, the CT findings and symptoms worsened.
  • Complete remission was achieved after systemic chemotherapy and there have been no event in the two years since diagnosis.
  • Choriocarcinoma is a rare malignant tumor developing after pregnancy, with frequent metastases to the lung.
  • Since, owing to recent advances of cancer chemotherapy, choriocarcinoma is now curable tumor, physicians must suspect this disease in cases of pulmonary embolisms in women.
  • [MeSH-major] Choriocarcinoma / complications. Lung Neoplasms / complications. Pulmonary Embolism / etiology

  • Genetic Alliance. consumer health - Choriocarcinoma.
  • Genetic Alliance. consumer health - Embolism.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19195206.001).
  • [ISSN] 1343-3490
  • [Journal-full-title] Nihon Kokyūki Gakkai zasshi = the journal of the Japanese Respiratory Society
  • [ISO-abbreviation] Nihon Kokyuki Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


29. Kanemitsu S, Tanabe S, Ohue K, Miyagawa H, Miyake Y, Okabe M: A ball-shaped thrombus of the tricuspid valve after VSD closure. Ann Thorac Cardiovasc Surg; 2009 Oct;15(5):346-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • No symptoms, coagulative disorders, or pulmonary embolisms were found.
  • A histological examination revealed the mass to be an organized thrombus with no tumor components.
  • [MeSH-minor] Adult. Glomerulonephritis, IGA / complications. Glomerulonephritis, IGA / drug therapy. Glucocorticoids / adverse effects. Humans. Male. Prednisolone / adverse effects. Thrombectomy. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Blood Clots.
  • MedlinePlus Health Information. consumer health - Heart Surgery.
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19901893.001).
  • [ISSN] 2186-1005
  • [Journal-full-title] Annals of thoracic and cardiovascular surgery : official journal of the Association of Thoracic and Cardiovascular Surgeons of Asia
  • [ISO-abbreviation] Ann Thorac Cardiovasc Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Glucocorticoids; 9PHQ9Y1OLM / Prednisolone
  •  go-up   go-down


30. Carron M, Ori C: Thrombolysis for massive pulmonary tumour embolism in a patient with cavoatrial renal carcinoma. Br J Anaesth; 2008 Aug;101(2):285-6
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Thrombolysis for massive pulmonary tumour embolism in a patient with cavoatrial renal carcinoma.
  • [MeSH-major] Carcinoma, Renal Cell / secondary. Heart Neoplasms / secondary. Neoplastic Cells, Circulating / drug effects. Pulmonary Embolism / drug therapy. Thrombolytic Therapy / methods
  • [MeSH-minor] Humans. Male. Middle Aged. Tissue Plasminogen Activator / therapeutic use

  • Genetic Alliance. consumer health - Embolism.
  • MedlinePlus Health Information. consumer health - Pulmonary Embolism.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18614604.001).
  • [ISSN] 1471-6771
  • [Journal-full-title] British journal of anaesthesia
  • [ISO-abbreviation] Br J Anaesth
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] England
  • [Chemical-registry-number] EC 3.4.21.68 / Tissue Plasminogen Activator
  •  go-up   go-down






Advertisement